Moderna's cancer vaccine as regulatory capture
The guest argued Moderna's cancer immunotherapy, a decades-old technique funded by public research, is being patented and priced at $500k as a form of regulatory capture rather than a novel breakthrough.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.